Thromboembolism Pipeline Review, H2 2018 - 10 Companies & Drug Profiles - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Thromboembolism - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Thromboembolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 5, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction

2. Report Coverage

3. Thromboembolism - Overview

4. Thromboembolism - Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Pipeline by Universities/Institutes

8. Products under Development by Companies

9. Products under Development by Universities/Institutes

10. Thromboembolism - Therapeutics Assessment

11. Assessment by Target

12. Assessment by Mechanism of Action

13. Assessment by Route of Administration

14. Assessment by Molecule Type

15. Thromboembolism - Companies Involved in Therapeutics Development

Bayer AG China Biologic Products Inc Daiichi Sankyo Co Ltd F. Hoffmann-La Roche Ltd GC Pharma Ionis Pharmaceuticals Inc Johnson & Johnson Portola Pharmaceuticals Inc Tetherex Pharmaceuticals Corp Verseon Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wztcxc/thromboembolism?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006078/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 02:51 PM/DISC: 09/25/2018 02:51 PM


Update hourly